“We know more than two billion people worldwide have not received a single dose of vaccine,” said David Veesler, associate professor of biochemistry at UW School of Medicine and co-developer of the vaccine. These attributes could enable vaccination at a global scale by reaching people in areas where medical, transportation, and storage resources are limited. The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond.
The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria. South Korea to purchase 10 million doses for domestic useĪ vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older.University of Washington to waive royalty fees for the duration of the pandemic.The protein-based vaccine, now called SKYCovione, does not require deep freezing.Clinical testing found the vaccine outperforms Oxford/AstraZeneca’s.
0 kommentar(er)
